Lista de obras - Philip J Lowe - Dominio Público Uruguay

A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab.

artículo científico publicado en 2006

Applying physiological and biochemical concepts to optimize biological drug development.

artículo científico publicado en 2010

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations

artículo científico publicado en 2009

Biliary protein output by isolated perfused rat livers. Effects of bile salts ⬇️

artículo científico publicado el 15 de febrero de 1983

Breakdown of hepatic tight junctions during reoxygenation injury

scientific article published on 01 June 1992

Bridging Clinical Outcomes of Canakinumab Treatment in Patients With Rheumatoid Arthritis With a Population Model of IL‐1β Kinetics ⬇️

artículo científico publicado el 26 de septiembre de 2012

Calcitonin and insulin in isobutylcyanoacrylate nanocapsules: protection against proteases and effect on intestinal absorption in rats

scientific article published on 01 July 1994

Colonic absorption of human calcitonin in man

scientific article published on 01 November 1992

Effect of taurochenodeoxycholate or tauroursodeoxycholate upon biliary output of phospholipids and plasma-membrane enzymes, and the extent of cell damage, in isolated perfused rat livers.

artículo científico publicado en 1983

Fluorescence anisotropy from diphenylhexatriene in rat liver plasma membranes

artículo científico publicado en 1982

From Target Selection to the Minimum Acceptable Biological Effect Level for Human Study: Use of Mechanism-based PK/PD Modeling to Design Safe and Efficacious Biologics ⬇️

artículo científico publicado el 19 de febrero de 2011

In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes

scientific article published on 13 April 2009

Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys.

artículo científico publicado en 2015

Membrane damage caused by bile salts [proceedings]

artículo científico publicado en 1980

New approach to measure protein binding based on a parallel artificial membrane assay and human serum albumin

artículo científico publicado en 2008

Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE.

artículo científico publicado en 2011

Omalizumab in asthma: an update on recent developments

artículo científico

Omalizumab in the treatment of severe allergic (IgE-mediated) asthma: an update on recent developments

On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.

scientific article published on 29 December 2009

On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach.

artículo científico publicado en 2005

P02-026 - Model-based characterization of the PKPD relationship for canakinumab in CAPS: a step towards personalized

artículo científico publicado en 2013

Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody

artículo científico publicado en 2012

Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects

artículo científico publicado en 2014

Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses.

artículo científico publicado en 2006

Population modeling of filgrastim PK-PD in healthy adults following intravenous and subcutaneous administrations.

artículo científico publicado en 2010

Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.

artículo científico publicado en 2011

Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations.

artículo científico publicado en 2009

Rapid kinetic analysis of the bile-salt-dependent secretion of phospholipid, cholesterol and a plasma-membrane enzyme into bile.

artículo científico publicado en 1984

Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma.

artículo científico publicado en 2009

Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE.

artículo científico publicado en 2014

Simplification of complex physiologically based pharmacokinetic models of monoclonal antibodies.

artículo científico publicado en 2014

Visualization and communication of pharmacometric models with berkeley madonna

artículo científico publicado en 2014

“Quantitative Pharmacology: An introduction to integrative pharmacokinetic‐pharmacodynamic analysis” ⬇️

artículo científico publicado el 19 de diciembre de 2012

Lista de obras de Philip J Lowe

A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab.

Applying physiological and biochemical concepts to optimize biological drug development.

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations

Biliary protein output by isolated perfused rat livers. Effects of bile salts ⬇️

Breakdown of hepatic tight junctions during reoxygenation injury

Bridging Clinical Outcomes of Canakinumab Treatment in Patients With Rheumatoid Arthritis With a Population Model of IL‐1β Kinetics ⬇️

Calcitonin and insulin in isobutylcyanoacrylate nanocapsules: protection against proteases and effect on intestinal absorption in rats

Colonic absorption of human calcitonin in man

Effect of taurochenodeoxycholate or tauroursodeoxycholate upon biliary output of phospholipids and plasma-membrane enzymes, and the extent of cell damage, in isolated perfused rat livers.

Fluorescence anisotropy from diphenylhexatriene in rat liver plasma membranes

From Target Selection to the Minimum Acceptable Biological Effect Level for Human Study: Use of Mechanism-based PK/PD Modeling to Design Safe and Efficacious Biologics ⬇️

In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes

Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys.

Membrane damage caused by bile salts [proceedings]

New approach to measure protein binding based on a parallel artificial membrane assay and human serum albumin

Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE.

Omalizumab in asthma: an update on recent developments

Omalizumab in the treatment of severe allergic (IgE-mediated) asthma: an update on recent developments

On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.

On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach.

P02-026 - Model-based characterization of the PKPD relationship for canakinumab in CAPS: a step towards personalized

Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody

Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects

Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses.

Population modeling of filgrastim PK-PD in healthy adults following intravenous and subcutaneous administrations.

Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.

Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations.

Rapid kinetic analysis of the bile-salt-dependent secretion of phospholipid, cholesterol and a plasma-membrane enzyme into bile.

Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma.

Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE.

Simplification of complex physiologically based pharmacokinetic models of monoclonal antibodies.

Visualization and communication of pharmacometric models with berkeley madonna

“Quantitative Pharmacology: An introduction to integrative pharmacokinetic‐pharmacodynamic analysis” ⬇️